Review Article

Update on the Use of Mesenchymal Stem Cells and their Products in Hematopoietic Stem Cell Transplantation

Khalid Ahmed Al-Anazi* and Ahmed Ayyad and Solaf Kanfer

Published: 29 November, 2023 | Volume 7 - Issue 1 | Pages: 024-033

Graft Versus Host Disease (GVHD) is a major limitation to the success of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as Steroid-Refractory (SR) acute GVHD carries poor prognosis due to the absence of an efficacious second-line therapy. Mesenchymal Stem Cells (MSCs) which have immunosuppressive, immunomodulatory, and regenerative properties may become a highly effective therapeutic modality for SR-GVHD in the near future. 
MSCs have already been approved to treat childhood SR-GVHD in Japan, and they have been conditionally licensed in New Zealand and Canada. It is expected that MSCs will be approved for the treatment of SR-GVHD in adults in Europe, North America, and other parts of the world within a few years. Utilization of the recently introduced techniques including the use of MSC products such as exosomes and Extracellular Vesicles (ECVs) instead of the parent MSCs, robotic manufacturing technology, and genetic engineering of MSCs will ultimately overcome the remaining obstacles facing the widespread utilization of MSCs and their products as therapeutics not only in HSCT but also in other medical fields. The aim of this review is to provide an update on the remarkable progress achieved in the use of MSCs and their products in the field of HSCT.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001032 Cite this Article Read Full Article PDF


Hematopoietic stem cell transplantation; Graft versus host disease; Mesenchymal stem cells; Exosomes; Extracellular vesicles


  1. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013 Jan 10;45(1):e2. doi: 10.1038/emm.2013.2. PMID: 23306700; PMCID: PMC3584660.
  2. Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int. 2020 Apr 7; 20:114. doi: 10.1186/s12935-020-01193-z. PMID: 32280306; PMCID: PMC7137413.
  3. Wolff D, Fatobene G, Rocha V, Kröger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transplant. 2021 Sep;56(9):2079-2087. doi: 10.1038/s41409-021-01389-5. Epub 2021 Jul 3. PMID: 34218265; PMCID: PMC8410585.
  4. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft VersusHost Disease: A Comprehensive Review. Anticancer Res. 2017 Apr;37(4):1547-1555. doi: 10.21873/anticanres.11483. PMID: 28373413.
  5. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008 Dec 10;26(35):5728-34. doi: 10.1200/JCO.2008.17.6545. Epub 2008 Nov 3. PMID: 18981462; PMCID: PMC2645611.
  6. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011 Mar 17;117(11):3214-9. doi: 10.1182/blood-2010-08-302109. Epub 2011 Jan 24. PMID: 21263156; PMCID: PMC3062319.
  7. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991 Jun;51(6):1197-203. doi: 10.1097/00007890-199106000-00010. PMID: 2048196.
  8. Vargas-Díez E, Fernández-Herrera J, Marin A, Cámara R, García-Díez A. Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. Br J Dermatol. 2003 Jun;148(6):1129-34. doi: 10.1046/j.1365-2133.2003.05336.x. PMID: 12828739.
  9. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987 Dec;67(4):397-406. doi: 10.1111/j.1365-2141.1987.tb06160.x. PMID: 3322360.
  10. Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023 Jun 8;9(1):27. doi: 10.1038/s41572-023-00438-1. PMID: 37291149.
  11. Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, Hexner EO, Rösler W, Etra AM, Sandhu K, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Adv. 2023 Aug 22;7(16):4479-4491. doi: 10.1182/bloodadvances.2023009885. PMID: 37315175; PMCID: PMC10440469.
  12. Kasikis S, Etra A, Levine JE. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease. BioDrugs. 2021 Jan;35(1):19-33. doi: 10.1007/s40259-020-00454-7. PMID: 33201499; PMCID: PMC7855093.
  13. Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets. 2021 Sep;25(9):761-771. doi: 10.1080/14728222.2021.1992383. Epub 2021 Nov 1. PMID: 34669521; PMCID: PMC8602762.
  14. Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020 May;34(5):1229-1240. doi: 10.1038/s41375-020-0804-2. Epub 2020 Apr 3. PMID: 32242050; PMCID: PMC7192843.
  15. Servais S, Baron F, Lechanteur C, Seidel L, Baudoux E, Briquet A, Selleslag D, Maertens J, Poire X, Schroyens W, Graux C, De Becker A, Zachee P, Ory A, Herman J, Kerre T, Beguin Y. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Front Immunol. 2023 Feb 1; 14:1106464. doi: 10.3389/fimmu.2023.1106464. PMID: 36817464; PMCID: PMC9929549.
  16. Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, Yu J, Huang H. Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Sep;25(9):1898-1907. doi: 10.1016/j.bbmt.2019.05.036. Epub 2019 Jun 6. PMID: 31176790.
  17. Chen J, Wang H, Zhou J, Feng S. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2020 Aug 17; 11:2040620720948743. doi: 10.1177/2040620720948743. PMID: 32874483; PMCID: PMC7436797.
  18. Man Y, Lu Z, Yao X, Gong Y, Yang T, Wang Y. Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation. Front Immunol. 2022 Jun 2; 13:911174. doi: 10.3389/fimmu.2022.911174. PMID: 35720412; PMCID: PMC9202575.
  19. Prabahran A, Koldej R, Chee L, Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv. 2022 Mar 22;6(6):1947-1959. doi: 10.1182/bloodadvances.2021004537. PMID: 34492685; PMCID: PMC8941468.
  20. Xiao Y, Song J, Jiang Z, Li Y, Gao Y, Xu W, Lu Z, Wang Y, Xiao H. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci. 2014 Apr 30;11(6):652-7. doi: 10.7150/ijms.6337. PMID: 24834012; PMCID: PMC4021098.
  21. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood. 2012 Feb 23;119(8):1801-9. doi: 10.1182/blood-2011-10-384354. Epub 2012 Jan 6. PMID: 22228625; PMCID: PMC3293637.
  22. Anazi AlKA, Jasser AlAM. Mesenchymal stem cells-their antimicrobial effects and their promising future role as novel therapies of infectious complications in high-risk patients. In: Progress in stem cell transplantation. Edited by: Demirer T. Intech Open. 2015. doi: 10.5772/ 60640
  23. Abdal Dayem A, Lee SB, Kim K, Lim KM, Jeon TI, Seok J, Cho AS. Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming. Int J Mol Sci. 2019 Apr 18;20(8):1922. doi: 10.3390/ijms20081922. PMID: 31003536; PMCID: PMC6514654.
  24. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia Histochem Cytobiol. 2006;44(4):215-30. PMID: 17219716.
  25. Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013 Jul;28(4):387-402. doi: 10.3904/kjim.2013.28.4.387. Epub 2013 Jul 1. PMID: 23864795; PMCID: PMC3712145.
  26. Squillaro T, Peluso G, Galderisi U. Clinical Trials with Mesenchymal Stem Cells: An Update. Cell Transplant. 2016;25(5):829-48. doi: 10.3727/096368915X689622. Epub 2015 Sep 29. PMID: 26423725.
  27. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. doi: 10.1080/14653240600855905. PMID: 16923606.
  28. Leyendecker A Jr, Pinheiro CCG, Amano MT, Bueno DF. The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivoTreatment of Immune-Related Diseases: A Systematic Review. Front Immunol. 2018 Sep 11; 9:2056. doi: 10.3389/fimmu.2018.02056. PMID: 30254638; PMCID: PMC6141714.
  29. Sarvar DP, Effatpanah H, Akbarzadehlaleh P, Shamsasenjan K. Mesenchymal stromal cell-derived extracellular vesicles: novel approach in hematopoietic stem cell transplantation. Stem Cell Res Ther. 2022 May 16;13(1):202. doi: 10.1186/s13287-022-02875-3. PMID: 35578300; PMCID: PMC9109321.
  30. De Luca L, Trino S, Laurenzana I, Lamorte D, Caivano A, Del Vecchio L, Musto P. Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation? Int J Mol Sci. 2017 May 9;18(5):1022. doi: 10.3390/ijms18051022. PMID: 28486431; PMCID: PMC5454935.
  31. Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy. 2009;11(5):503-15. doi: 10.1080/14653240903193806. PMID: 19728189; PMCID: PMC2766085.
  32. Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol. 2021 Oct 26; 12:761616. doi: 10.3389/fimmu.2021.761616. PMID: 34764962; PMCID: PMC8577186.
  33. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013 Jan 10;45(1):e2. doi: 10.1038/emm.2013.2. PMID: 23306700; PMCID: PMC3584660.
  34. Burnham AJ, Daley-Bauer LP, Horwitz EM. Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv. 2020 Nov 24;4(22):5877-5887. doi: 10.1182/bloodadvances.2020002646. PMID: 33232479; PMCID: PMC7686890.
  35. Wu KH, Wu HP, Chan CK, Hwang SM, Peng CT, Chao YH. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: from bench to bedsides. Cell Transplant. 2013;22(4):723-9. doi: 10.3727/096368912X655217. Epub 2012 Oct 12. PMID: 23068433.
  36. Petinati N, Drize N, Sats N, Risinskaya N, Sudarikov A, Drokov M, Dubniak D, Kraizman A, Nareyko M, Popova N, Firsova M, Kuzmina L, Parovichnikova E, Savchenko V. Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem Cells Int. 2018 Apr 10;2018: 6495018. doi: 10.1155/2018/6495018. PMID: 29760731; PMCID: PMC5914104.
  37. Liu XD, Fan ZP, Peng YW, Huang F, Jiang QL, Zhang X, Yu GP, Zhao J, Sun J, Xiang P, Liu QF. [The outcome and safety of mesenchymal stem cells from bone marrow of a third party donor in treatment of secondary poor graft function following allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):98-102. Chinese. PMID: 22730656.
  38. Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F, Fan Z, Zhou H, Wu X, Yu G, Zhang X, Li Y, Xiao Y, Song C, Xiang AP, Liu Q. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23(9):1087-98. doi: 10.3727/096368912X661319. PMID: 23294601.
  39. McGuirk JP, Metheny L 3rd, Pineiro L, Litzow M, Rowley SD, Avni B, Tamari R, Lazarus HM, Rowe JM, Sheleg M, Rothenstein D, Halevy N, Zuckerman T. Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study. Bone Marrow Transplant. 2023 Nov;58(11):1189-1196. doi: 10.1038/s41409-023-02068-3. Epub 2023 Aug 8. PMID: 37553467; PMCID: PMC10622312.
  40. Najima Y, Ohashi K. Mesenchymal stem cells. The first approved stem cell drug in Japan. J Hemat Cell Transplant. 2017; 6 (3): 125-132. doi: 10.7889/hct16-031
  41. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013; 13(4):392-402. doi: 10.1016/j.stem.2013.09.006. PMID: 24094322.
  42. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013 Jan;91(1):19-26. doi: 10.1038/icb.2012.56. Epub 2012 Oct 23. PMID: 23090487.
  43. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012 Apr 25;12(5):383-96. doi: 10.1038/nri3209. PMID: 22531326.
  44. Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP, Liu Q. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022 Mar 7;15(1):22. doi: 10.1186/s13045-022-01240-4. PMID: 35255929; PMCID: PMC8900437.
  45. Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T, Maekawa T. Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations. Stem Cells. 2018 Mar;36(3):434-445. doi: 10.1002/stem.2759. Epub 2017 Dec 27. PMID: 29239062.
  46. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, Taniguchi S, Imamura M, Ando K, Kato S, Mori T, Teshima T, Mori M, Ozawa K. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013 Aug;98(2):206-13. doi: 10.1007/s12185-013-1399-4. Epub 2013 Jul 17. PMID: 23860964.
  47. Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016 Feb;103(2):243-50. doi: 10.1007/s12185-015-1915-9. Epub 2015 Nov 25. PMID: 26608364.
  48. Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. PLoS One. 2015 Aug 31; 10(8):e0136991. doi: 10.1371/journal.pone.0136991. PMID: 26323092; PMCID: PMC4554731.
  49. Morata-Tarifa C, Macías-Sánchez MDM, Gutiérrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther. 2020 Feb 18;11(1):64. doi: 10.1186/s13287-020-01592-z. PMID: 32070420; PMCID: PMC7027118.
  50. Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, Prasad VK, Kebriaei P, Ringden O. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016 Jan; 3(1):e45-52. doi: 10.1016/S2352-3026(15)00224-0. Epub 2015 Nov 27. PMID: 26765648.
  51. Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 2022 Mar 4;13(1):93. doi: 10.1186/s13287-022-02751-0. PMID: 35246235; PMCID: PMC8895864.
  52. Li T, Luo C, Zhang J, Wei L, Sun W, Xie Q, Liu Y, Zhao Y, Xu S, Wang L. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021 Apr 20;12(1):246. doi: 10.1186/s13287-021-02304-x. PMID: 33879242; PMCID: PMC8056684.
  53. Wang L, Zhu CY, Ma DX, Gu ZY, Xu CC, Wang FY, Chen JG, Liu CJ, Guan LX, Gao R, Gao Z, Fang S, Zhuo DJ, Liu SF, Gao CJ. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Ann Hematol. 2018 Oct;97(10):1941-1950. doi: 10.1007/s00277-018-3384-8. Epub 2018 Jun 8. PMID: 29947972.
  54. Munneke JM, Spruit MJ, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. Transplantation. 2016 Nov;100(11):2309-2314. doi: 10.1097/TP.0000000000001029. PMID: 26714122.
  55. Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Cytotherapy. 2016 Feb;18(2):172-85. doi: 10.1016/j.jcyt.2015.11.010. PMID: 26794711.
  56. Li R, Tu J, Zhao J, Pan H, Fang L, Shi J. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia? -a systematic review and meta-analysis. Stem Cell Res Ther. 2021 Feb 4;12(1):106. doi: 10.1186/s13287-021-02170-7. PMID: 33541414; PMCID: PMC7860635.
  57. Kurtzberg J, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, Satwani P, Teira P, Hayes J, Burke E; MSB-275 Study Group. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Biol Blood Marrow Transplant. 2020 May;26(5):855-864. doi: 10.1016/j.bbmt.2020.01.026. Epub 2020 Feb 7. PMID: 32044400; PMCID: PMC8292970.
  58. Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 May;26(5):835-844. doi: 10.1016/j.bbmt.2019.08.029. Epub 2019 Sep 7. PMID: 31505228; PMCID: PMC7060124.
  59. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D; MSB-GVHD001/002 Study Group. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 May;26(5):845-854. doi: 10.1016/j.bbmt.2020.01.018. Epub 2020 Feb 1. PMID: 32018062; PMCID: PMC8322819.
  60. Kurtzburg J.LBA17 (Abstract): Long-term survival in children treated with Remestemcel-L for steroid-refractory acute GVHD. Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. 2023. Orlando, Florida, USA.
  61. Fitch J. Mesoblast receives complete response from US Food and Drug Administration for Biologics License Application for steroid-refractory acute graft versus host disease in children. Contemp Pediatr.2023. https://investorsmedia.mesoblast.com/static-files/422cd6da-a0b9-49cf-a177- 7fd106f111f2
  62. Fujii S, Miura Y. Immunomodulatory and Regenerative Effects of MSC-Derived Extracellular Vesicles to Treat Acute GVHD. Stem Cells. 2022 Nov 29;40(11):977-990. doi: 10.1093/stmcls/sxac057. PMID: 35930478.
  63. Stenger E, Giver CR, Langston A, Kota D, Das PK, Chinnadurai R, Galipeau J, Waller EK, Qayed M. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease. Front Immunol. 2022 Sep 14; 13:959658. doi: 10.3389/fimmu.2022.959658. PMID: 36189324; PMCID: PMC9515357.
  64. Wang B, Hu Y, Liu L, Hu K, Tie R, He Y, Fu S, Zhu N, Luo Y, Yu X, Huang H. Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jun;21(6):1020-8. doi: 10.1016/j.bbmt.2015.02.013. Epub 2015 Feb 20. PMID: 25708216.
  65. Zhang LS, Liu QF, Huang K, Zhang Y, Fan ZP, Huang SL. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease]. Zhonghua Nei Ke Za Zhi. 2009 Jul;48(7):542-6. Chinese. PMID: 19957792.
  66. Erkers T, Kaipe H, Nava S, Molldén P, Gustafsson B, Axelsson R, Ringdén O. Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111) indium radiolabeling. Stem Cells Dev. 2015 Jan 15;24(2):253-63. doi: 10.1089/scd.2014.0265. PMID: 25162829; PMCID: PMC4291217.
  67. Ringden O. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease and graft failure after hematopoietic stem cell transplantation and future challenges. In: Mesenchymal Stem Cell Therapy. Chase IG, Vemuri MC, eds. Springer Verlag, Humana Press, New York. 2013; 173-206.
  68. Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Arsenijevic N, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Eye Diseases. Adv Exp Med Biol. 2018; 1089:47-57. doi: 10.1007/5584_2018_219. PMID: 29774506.
  69. Harrell CR, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Ocular Graft-Versus-Host Disease. Int J Mol Sci. 2022 Oct 31;23(21):13254. doi: 10.3390/ijms232113254. PMID: 36362040; PMCID: PMC9656879.
  70. Weng J, He C, Lai P, Luo C, Guo R, Wu S, Geng S, Xiangpeng A, Liu X, Du X. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012 Dec;20(12):2347-54. doi: 10.1038/mt.2012.208. Epub 2012 Oct 16. PMID: 23070118; PMCID: PMC3519994.
  71. Keshavarz Shahbaz S, Mansourabadi AH, Jafari D. Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease. Clin Exp Immunol. 2022 May 13;208(1):12-24. doi: 10.1093/cei/uxac016. PMID: 35274673; PMCID: PMC9113247.
  72. Ochs J, Barry F, Schmitt R, Murphy M. Advances in automation for the production of clinical-grade mesenchymal stromal cells: the AUTOSTEM robotic platform. Cell Gene Ther Insights. 2017; 3(8): 739-748. doi: 10.18609/ cgti.2017.073
  73. Kimbrel EA, Lanza R. Next-generation stem cells - ushering in a new era of cell-based therapies. Nat Rev Drug Discov. 2020 Jul;19(7):463-479. doi: 10.1038/s41573-020-0064-x. Epub 2020 Apr 6. PMID: 32612263.
  74. Sarsenova M, Kim Y, Raziyeva K, Kazybay B, Ogay V, Saparov A. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells. Front Immunol. 2022 Sep 23; 13:1010399. doi: 10.3389/fimmu.2022.1010399. PMID: 36211399; PMCID: PMC9537745.


Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?